KetoTV reported on Thursday that Nicolas Tzenios plans to launch a keto clinical trial under a partnership with KGK Science Inc, a contract research organisation.
Hon Prof Dr Nicolas Tzenios is the chairman of medical research hub TRCGEN+. He is the author of 'Nic's Keto Diet', a book which is now available in four languages, and created a Keto postgraduate course that is taught in universities and colleges across the globe. TRCGEN+ sponsors medical research clinical trials including Keto diet effects and a genetic research related to specific genetic cancer treatment approach with Kursk State Medical University.
Through this research programme, Hon Prof Tzenios hopes to prove his 'Friendly LDL Theory', which suggests that in the absence of elevated glucose, low-density lipoprotein (LDL) does not oxidise or form plaque and has anti-inflammatory effects. He believes that elevated glucose, rather than fat, results in the onset of cardiovascular and diet-related diseases.
In addition, Hon Prof Tzenios is applying to patent his Friendly LDL Theory. This concept is inspired by the success of the keto diet, which involves the ingestion of high-fat, low-carb foods. If corroborated, his theory has the potential to greatly impact the realm of dietary science, KetoTV said.
Sanofi reports data showing high-dose flu vaccine delivers superior protection for older adults
Avacta reports promising Phase 1a data for faridoxorubicin at ESMO 2025
Jacobio Pharma partners with Oceanpine Capital to focus on core oncology pipeline
Johnson & Johnson to separate its Orthopaedics business as standalone DePuy Synthes
Ascletis selects once-monthly SQ GLP-1R/GIPR dual peptide agonist, ASC35, for clinical development
Autonomix Medical secures new US patent to expand precision nerve-targeted therapies
Merck completes acquisition of Verona Pharma to expand cardio-pulmonary portfolio
Amgen offers Repatha through AmgenNow direct-to-patient programme